Literature DB >> 27939062

Dawn of a new therapeutic era for spinal muscular atrophy.

Thomas H Gillingwater1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27939062     DOI： 10.1016/S0140-6736(16)32390-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

2.  Notch Signaling Mediates Astrocyte Abnormality in Spinal Muscular Atrophy Model Systems.

Authors:  Kazuki Ohuchi; Michinori Funato; Yuta Yoshino; Shiori Ando; Satoshi Inagaki; Arisu Sato; Chizuru Kawase; Junko Seki; Toshio Saito; Hisahide Nishio; Shinsuke Nakamura; Masamitsu Shimazawa; Hideo Kaneko; Hideaki Hara
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

Review 3.  Therapeutic strategies for spinal muscular atrophy: SMN and beyond.

Authors:  Melissa Bowerman; Catherina G Becker; Rafael J Yáñez-Muñoz; Ke Ning; Matthew J A Wood; Thomas H Gillingwater; Kevin Talbot
Journal:  Dis Model Mech       Date:  2017-08-01       Impact factor: 5.758

Review 4.  Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.

Authors:  Hannah K Shorrock; Thomas H Gillingwater; Ewout J N Groen
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.